The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Actually, reading again I think it's retrospective. Hopefully problems sorted?
GLA
Field 'stuff' happening just now!
http://pipeline.wyo.gov/RepByCompsundr.cfm?oops=ID82708&RequestTimeOut=65000&nOpco=1769
BFU 23-27V
http://pipeline.wyo.gov/Wellapi.cfm?oops=ID8221&nAPINO=934819
Sundry – Subsequent Report 10/03/2023 (
Well 934819 was originally included in the approved order in Docket 775-2022 through April 9,
2023. The well was removed from the approved extension order in Docket 425-2023 good through October 7, 2023. SWP had to emergency flare for 4 days (910 Mcf Cum) in September 2023 due to the commissioning of the new high pressure separator at the wellsite as well as high line pressures in the field from adjustments being made at the processing plant.
BFU 22-27V
http://pipeline.wyo.gov/Wellapi.cfm?oops=ID8221&nAPINO=934637
Sundry – Notice of Intent 10/03/2023 (MDY)
SWP requests approval to emergency flare a cumulative volume of up to 6,000 Mcf for 5-7 days
in October 2023 due to upset operational conditions in the field. The well has experienced a
paraffin plugged flowline. After removing the restriction in the flowline, the well needs to
be flared to drop the tubing pressure prior to turning the gas back to the processing plant
safely. Well 934637 was originally included in the approved order in Docket 775-2022 through
April 9, 2023. The well was removed from the approved extension order in Docket 425-2023 good through October 7, 2023. Sundry – Subsequent Report 10/03/2023 (MDY)
Well 934637 was originally included in the approved order in Docket 775-2022 through April 9,
2023. The well was removed from the approved extension order in Docket 425-2023 good through
October 7, 2023. SWP had to emergency flare a cumulative volume of 14,957 Mcf in July, August and September 2023 due to upset operational conditions in the field. The well experienced a paraffin plugged flowline in July and August. After removing the restriction in the flowline, the well had to be flared to drop the tubing pressure prior to turning the gas back to the processing plant safely. The reasoning for flaring in September was due to the well being
down for a heater treater repair. After the repairs were complete and the well was returned
to production, the well had to be flared to drop the tubing pressure prior to turning the gas
back to the processing plant safely.
GLA
Another SINT (‘Systematic Internaliser’ – II, Bank, Hedge Fund, etc., between clients) trade …
2023-10-05T14:09:57+01:00 GBp 1.614 25000000 40,250,000 Off-book SINT
I suppose this will lower the VWAP? Not that that’s relevant of course.
GLA
MIC code ‘SINT’ trade …
2023-10-04T13:57:30+01:00 GBp 2 10000000 20,000,000 Off-book SINT
So II (‘Systematic Internaliser’) trading on own account between clients. Closed ‘market place’, no MM’s.
Make of that what you will.
GLA
@desert. Revenue just short of ~$5m for last reported quarter, but net loss (~$25m).
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001811764/000181176423000038/pnt-20230630.htm
Balance sheet looks OK, so think Lily got a good deal – a number of ‘collaborations’ and ‘partnerships’ to factor in though, so (as with CanSEEK™) not all future revenue to Lily.
GLA
Whether CanSEEK™ or other approach to targeting, radiotherapy really does need to need to be highly targeted. The alpha, beta or gamma emissions from the radio isotopes being ‘transported’ through the body in the form of radioligands are not neutralised by the ligand molecule, the radiation just keeps on being emitted (determined by the isotope half-life) and so risks tissue, cell, DNA damage etc. You can’t turn the radiation off – unlike the inert state of ‘transported’ chemotherapy, for example Prodoxorubicin with AVA6000. Add in the need for nearby and near real-time manufacturing, it just adds to the challenge. Just highlights the enormous potential of the pre|CISIONTM platform with, potentially, a range of Chemo/MMAE warheads.
Anyway, suspect Lily getting a bit worried by the Novartis pipeline …
https://www.novartis.com/research-development/novartis-pipeline?search_api_fulltext=&field_therapeutic_area%5B%5D=2771
Now which other BP have oncology pipeline ‘deficits’?
GLA
Of 35 producing wells a total of -116 days lost against a max of 31x35=1085.
Plus 1 well with 0 production on 0 days in Aug that was producing in Jul.
The lost days are somewhat ‘skewed’ to the larger wells, but the real problem is that historical levels of production have not been achieved, which suggests that GGS / injection being deployed with caution.
GLA
To add some more detail.
Top 7 (those over 2000) …
BFU 32-27V, 3405
BFU 34-20V, 3198 (down -1288)
BFU Fed 11-22V, 3123
BFU 44-22V, 2903
BFU FED 32-21V, 2483
BFU 44-21V, 2176
BFU 21-35-76 ST A SN 3H, 2066
Wells that produced 150 barrels more in Aug vs July …
BFU 21-35-76 ST A SN 3H, 2066 +771 on 21 days (plus 4694 gas and 4606 water, so ‘activity’)
BFU 21-34V, 835 +571 on 31 days (31 days in July also, so good increase)
BFU 23-27V, 1464 +169 on 23 days (plus 11651 gas, so something happening)
BFU 14-23V, 927 +153 on 29 days
BFU 23-14V, 670 + 151 on 24 days
11 more wells with increases totalling +645. Overall vs Jul, 16 wells higher, total gained +2460.
Wells that produced 150 barrels less in Aug vs July …
BFU 34-20V, 3198 -1288 on -7 fewer (24) days (plus 13902 gas!)
BFU FEDERAL 41-34H, 720 -856 on 31 days
BFU FED 11-28V, 620 -515 on -14 fewer (17) days
BFU FED 21-21V, 563 -462 on -8 fewer (21) days
COLE CREEK 31-17, 0, -428 on 0 days (so not producing)
BFU FED 33-23V, 1072 -379 on -1 fewer days
BFU Fed 41-20V, 290 -187 on 10 fewer (19) days
13 more wells with decrease totalling -641. Overall vs Jul, 20 wells lower, total lost -4756.
Reconciliation, July 37,831 plus +2460 less – 4756 = 35,535
Problem (obvious) more losers with bigger losses, hope that this is indicative of GGS commissioning / tuning and a lot of other field improvement activity. Would be good to get a ‘flash’ report on September.
GLA
@Codej, agree. Very simple arithmetic), expect more from Coris and Launch. Interesting to see what Tony Gardiner has to say about DX co.'s.
GLA
From slide 8 …
“…giving a cash runway into H2 2024.”
Really simple ‘check’ of numbers – £41.78m end-2022 less £25.97m end-H1 = £15.81m net cash spent in 6 months, or £2.635m / month, add in a few more expensive staff and let’s say £3m / month, so realistically need to sort funding before end-Q1 24.
So time to publish peer-reviewed data, and therefore plenty of time to sort out (non-dilutive) funding.
GLA
Courtesy @Mstambo999 from twiX …
https://twitter.com/hashtag/AVCT?src=hashtag_click&f=live
Nice design, wood, granite (effect), plants, looks like we’re ‘green’ then.
(Is that David Wilson peeking out from the back, perhaps he’s now ‘chief stand designer’?).
GLA
In fact potentially so good it’s not just about delivering Chemo (Dox plus others) to the tumour safely.
7 Jan 2021 License Agreement with POINT Biopharma Inc.
“The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.”
Given the agreement with POINT is non-exclusive, after the first radiopharmaceutical, will we see other companies interested in licensing pre|CISIONTM in the same way POINT has for CanSEEK™?
Novartis and POINT) seem to be ‘leading the pack’?
Do we actually have to wait for POINT to confirm the first radioligand to be delivered by CanSEEK™? Or are there licensing opportunities to be had now for pre|CISIONTM delivery of radioligands?
GLA
For info …
https://www.takedaoncology.com/news/news-releases/takeda-receives-positive-CHMP-opinion-for-ADCETRIS-for-the-treatment-of-adult-patients-with-previously-untreated-CD30-stage-III-hodgkin-lymphoma-in-combination-with-AVD/
Takeda Phase 3 for ADCETRIS® (brentuximab vedotin) – note “in combination with doxorubicin ..”.
OK, looks very positive, but read down for the “Special Warnings and Precautions”.
Still waiting for Takeda to licence pre|CISION™ for AVA3996/2727D, given Velcade (bortezomib) off patent.
GLA
Https://www.youtube.com/watch?v=C7HAHG0-ncc
From PMH Capital on twiX – Avacta from ~6:30.
GLA
POO matters. Global oil supply matters. One is going up, the other seems to be going down ...
BBC Business Report just saying that “global oil prices have reached highest level for more than 10 months”, driven by production cuts in Saudi and Russia. “IEA has warned of a significant supply shortfall by the end of the year”.
Meanwhile COPL said (6 Sept RNS) – “The Company is focused on delivering production results in Q4 2023 …”.
Great timing.
GLA
This is a very good question.
Are the continuing patients still under the original trial protocol?
Have they exceeded the planned number of cycles?
Has the 3-weekly dosing level been increased to C6 level?
Etc. Many questions. Hope for some ‘illumination’ soon.
GLA
New 'insight' from Hurst - IPO. What, where, when, source, please @Hurst10.
GLA
US EIA short-term energy outlook, updated 12 Sept, also notes the continuing Saudi oil production cut …
https://www.eia.gov/outlooks/steo/report/index.php
Forecast Brent @ ~$93 through Q4/23 with a slight easing to average ~$88 in 2024 (note – WTI usually ~$4 lower).
Also forecasting an increase in US domestic oil production in 2024 (vs 2023).
6 Sept RNS states – “The Company is focused on delivering production results in Q4 2023 …”.
No hedge, oil price forecast to go up in Q4, US production to increase in 2024 (where from?). And, if you look through the report, US CO2 emissions remaining ‘stubbornly’ high – anyone help here?
GLA
Trial design seemed to be ‘modified’ during the presentation. Who knows what the plan is now?
Slide 10 – ‘Indicative Trial Design’, 2 groups of ‘Up to 20 Patients’ at ‘Dose 1’ and ‘Dose 2’ of AVA6000 vs ‘15-20 Patients Doxorubicin’.
Slide 21, 27 – ‘2 AVA6000 dose levels for Phase 1b’, but 2 x 24 patients AVA6000 and 12 Doxorubicin.
GLA
TTI-621 (Pfizer) …
https://www.pharmaceutical-technology.com/data-insights/tti-621-pfizer-follicular-lymphoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-234742&utm_campaign=recommended-articles
TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS) …
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS11593
MSK …
https://www.mskcc.org/cancer-care/clinical-trials/21-407
Investigator - Sujana Movva …
https://www.mskcc.org/cancer-care/doctors/sujana-movva#about_specialties
Clinical Trials Co-Investigated by Dr. Movva - A Phase 1a Study of AVA6000 in People with Solid Tumors ..
https://www.mskcc.org/cancer-care/clinical-trials/22-428
Safety and effects of TTI-621 in combination with doxorubicin …
https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/792ae267-45a6-4ae0-a0b0-158f4a2d3cfd/The%20safety%20and%20effects%20of%20TTI-621%20in%20combination%20with%20doxorubicin%20in%20people%20living%20with%20leiomyosarcoma.pdf
“The most severe side effects were thought to be caused by doxorubicin …”.
No doubt Dr Movva knows about a (much) better alternative to ‘straight’ dox?
Wonder how many more ‘combo’ therapies would benefit from AVA6000?
GLA